LunaRich is an exclusive soy powder that Reliv International says provides five to 10 times the amount of lunasin as ordinary soy powder.
Lunasin is the naturally occurring soy peptide that has been shown to be responsible for the cholesterol-lowering properties of soy, says dietary supplements brand Reliv International. The company says that its GlucAffect supplement, which is marketed to help against metabolic syndrome, now includes the company’s LunaRich ingredient. LunaRich is an exclusive soy powder that Reliv says provides five to 10 times the amount of lunasin as ordinary soy powder.
LunaRich was developed at the Missouri Plant Science Center (MPSC) exclusively for Reliv International. In a press release, the firm describes lunasin’s role in helping to lower cholesterol. “[A] naturally occurring soy peptide called lunasin targets cholesterol at an earlier stage, reducing the HMG-CoA without blocking it entirely. LunaRich soy powder harnesses the power of the lunasin peptide to balance cholesterol.” The company says that most cholesterol is produced in the liver by the HMG-CoA reductase gene.
The firm adds that unlike statins, which may block HMG-CoA but block them “too much,” a naturally occurring soy peptide like LunaRich can help target cholesterol at the earlier stage, “reducing the HMG-CoA without blocking it entirely.”
“[T]he increased levels of lunasin in LunaRich soy powder have given GlucAffect an even greater edge in the fight against metabolic syndrome,” added Reliv’s chief scientific officer Carl Hastings, PhD.
“In developing LunaRich for Reliv, we have maximized lunasin levels in soy,” added Alfredo Galvez, PhD, who Reliv says was the first scientist to discover lunasin.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.